1. POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS. (12th June 2019) Authors: Diefenbach, C.; Kahl, B.; Banerjee, L.; McMillan, A.; Ramchandren, R.; Miall, F.; Briones, J.; Cordoba, R.; Gonzalez‐Barca, E.; Panizo, C.; Hirata, J.; Chang, N.; Musick, L.; Abrisqueta, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. (17th June 2021) Authors: Bannerji, R.; Yuen, S.; Phillips, T.; Arthur, C.; Isufi, I.; Marlton, P.; Seymour, J. F.; Corradini, P.; Molinari, A.; Gritti, G.; Emmons, R.; Hirata, J.; Musick, L.; Saha, S.; Croft, B.; Flowers, C. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: McMillan, A.; Haioun, C.; Sancho, J.-M.; Viardot, A.; Rodriguez Izquierdo, A.; Donato Martin, E. M.; García-Sancho, A. M.; Sandoval-Sus, J.; Tilly, H.; Vandenberghe, E.; Hirata, J.; Choudhry, P.; Chang, Y. M.; Musick, L.; Matasar, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1075 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗